An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Inclusion Criteria:

Male or female adults ≥ 18 years of age.
Diagnosis of chronic plaque-type psoriasis for at least 6 months
Moderate to Severe plaque psoriasis as defined by BSA ≥10 PASI ≥12 IGA ≥3
Able to give written informed consent prior to performance of any study related procedures
Subject is able to attend Narrowband UVB phototherapy sessions three times a week and all other protocol specified visits
Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination.

Exclusion Criteria:

Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis
History of photosensitivity
Subject has used ustekinumab and/or anti-IL-17 biologic therapy within 24 weeks or other experimental or commercially available biologic immune modulator(s) within 12 weeks prior to the first IP dose.
Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin, apremilast and cyclosporine).
Patient used topical therapies to treat within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).
Initiated within 3 months, planned initiation of, or changes to, concomitant medications that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors ) during the trial
Active infections requiring antibiotics in the 2 weeks prior to Baseline
Patient received UVB phototherapy within 4 weeks of Baseline.
Patient received PUVA phototherapy within 4 weeks of Baseline.